Stepan D. Shceglov

Stepan D. Shceglov

Auto-generated profile, based on publicly available information

Stepan D. Shceglov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
GOG. A. Oborotov
G. A. Oborotov
MDM. V. Dmitrieva
M. V. Dmitrieva
AKA. P. Kolpaksidi
A. P. Kolpaksidi
SSS. D. Shceglov
S. D. Shceglov
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Background. Chemotherapy remains the mainstay of drug treatment for malignant neoplasms, but its effectiveness is often limited by the development of drug resistance, low selectivity, and toxicity of the drugs used. Gemcitabine therapy, one of the most commonly used chemotherapeutic drugs, has many limitations, such as a short half-life and rapid degradation of the drug in the body. To improve the therapeutic efficacy of gemcitabine, two main strategies have been proposed – chemical modification of the compound and the creation of delivery systems based on various nanocarriers, in particular liposomes.Aim. To systematize and summarize the literature data on the prospects of developing a liposomal gemcitabine delivery system.Materials and methods. The search for materials on the topic under study was carried out using the search and information and library databases PubMed, CyberLeninka, e-Library, ResearchGate. The search for publications was carried out for the period from 1997 to 2025 using keywords / phrases: “liposomes”, “liposome encapsulation”, “liposomal gemcitabine”, “liposomal gemcitabine pharmacokinetics”, etc.Results. To date, numerous models of liposomal forms of gemcitabine have been developed and are at the preclinical development stage, and only one of them, FF-10832, has reached phase I of clinical trials. According to the results of a comparative study of the traditional and nanostructured forms of gemcitabine presented in the analyzed publications, liposomal gemcitabine demonstrates a higher therapeutic effect in in vivo experiments due to increased bioavailability and targeted delivery to tumor cells. However, the main problem in creating an optimal liposomal composition of gemcitabine remains the low level of drug encapsulation in vesicles, which can be overcome by selecting a lipid composition or developing a rational loading method.Conclusion. The literature data on the use of gemcitabine in the treatment of malignant neoplasms and the prospects for developing its liposomal delivery system have been systematized and summarized. It has been shown that the inclusion of gemcitabine in liposomes allows eliminating the problems associated with antitumor therapy with this drug.

15 July 2026 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SSStepan D. Shceglov
Stepan D. Shceglov
ЩДЩеглов Степан Дмитриевич
Щеглов Степан Дмитриевич
YSYana O. Sadovskaya
Yana O. Sadovskaya
СОСадовская Я. О.
Садовская Я. О.
AKAnastasia O. Karimova
Anastasia O. Karimova
КМКозлова Ж. М.
Козлова Ж. М.
Background. One of the key components of innate immune signaling pathways, the STING (STimulator of INterferon Genes) protein, is currently a promising target for cancer immunotherapy. Activation of STING leads to the production of inflammatory cytokines, in particular type 1 interferons, which provide an antitumor immune response. The clinical potential of STING agonists is limited by their systemic toxicity due to their relatively non-specific action. One of the approaches to expand the therapeutic index of drugs is to modify the native structure of STING agonists to make them more sensitive to physiologically relevant stimuli. Another approach is to develop efficient delivery system that reduce the impact of encapsulated STING agonists on healthy tissues. Aim. Systematization and generalization the literature data on the development of delivery systems of STING agonists based on immunoconjugates, liposomes, and polymer nanoparticles. Results. The delivery systems discussed show significant potential for enhancing the efficacy of STING agonist-based immunotherapy for malignant neoplasms. As substances exhibiting therapeutically relevant activity in the nanomolar concentration range, STING agonists represent a suitable candidate as a payload of immunoconjugates. During the pharmaceutical development of such a delivery system, it is necessary to take into account the properties of its structural components, primarily the STING agonist itself. The result is almost always a unique product: a molecular construct capable of selectively delivering the STING activator to the tumor microenvironment while minimizing systemic side effects. Encapsulation of STING agonists, particularly cyclic dinucleotides, within nanoparticles serves as an effective tool for increasing their in vivo stability, improving cellular uptake, and reducing systemic toxicity. Conclusion. The development of innovative delivery systems is a critical factor for the successful clinical implementation of STING agonist-based biotherapy for malignant neoplasms. The flexibility of the structure of nanoplatforms allows for their further modification and optimization, including the improvements in manufacturing technology to obtain a stable product with specified characteristics.

26 June 2024 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SSS. D. Shceglov
S. D. Shceglov
Chemotherapy for cancer is associated with a significant risk of severe side effects due to the effects of cytostatics on healthy cells. Targeted oncotherapy is an innovative approach to cancer treatment that targets specific protein structures and metabolic pathways that are highly likely to be inherent in tumor cells. Historically, immunoconjugates (IC) were among the first targeted therapy agents, along with monoclonal antibodies, to be approbated and subsequently approved for clinical use. Traditionally, an IC is described as a monoclonal antibody covalently linked to a therapeutic component via a linker. Due to their vector component, these drugs allow the application of selective effects on epitope-defined targets, which significantly increases the therapeutic index of highly toxic antitumor agents. In addition, targeting therapy helps to overcome drug resistance of tumors and improve the prognosis of the disease. Herewith, the pharmaceutical design of IC requires comprehensive consideration of specific aspects such as physicochemical properties of the conjugated substance, optimal choice of immunoglobulin class G isotype, biochemical properties of the linker and conjugation methods. A comprehensive study of these aspects will not only optimize the design of IC, but will also contribute to the widespread use in clinical practice and expand the range of applications of such drugs. This review presents the evolution of the antibody – drug conjugate concept in the context of the application of these drugs in oncotherapy. The aspects of structure and specific features of strategies of drug-drug conjugation with monoclonal antibody, which are basic for IC design, are also discussed and summarized.

7 May 2025 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ESEkaterina Sanarova
Ekaterina Sanarova
LNLudmila Nikolaeva
Ludmila Nikolaeva
SSS. D. Shceglov
S. D. Shceglov
ZKZh. M. Kozlova
Zh. M. Kozlova
OOO. L. Orlova
O. L. Orlova
ALAnna Lantsova
Anna Lantsova
Introduction. The influence of the dosage form on the pharmacological effect has been known since ancient times. The strategy for the preparation of micellar dosage forms for active antitumour substances was formulated in the last century. However, it has become widespread in practice in recent decades. This is largely due to advances in the synthesis of new structural components for the formation of micellar carrier, as well as to the acquisition of better knowledge of biochemical processes occurring in the tumour cell.Text. This review is devoted to the achievements in the field of application of nanomicellar forms of antitumor drugs to improve the effectiveness of cancer therapy, which cover the period from 2019 to 2024. For this purpose, excipients used to obtain nanomicellar forms of antitumor substances are considered and analyzed, using docetaxel, paclitaxel, doxorubicin, and photosensitizers as examples. The creation of micellar forms allowed us to take a new look at these substances known in oncological practice.Conclusion. Available achievements in the field of nanomicelles application for increasing the effectiveness of antitumour substances undoubtedly show the promising development of this technological direction. However, there are still many unresolved issues related to the stability of nanomicelles when administered into the body, as well as legal regulation in the field of creation and introduction of this new pharmaceutical form. These questions still need to be resolved by pharmaceutical science.